Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 4/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | PROKR1 | Q8TCW9 | 3/20 | 0.36 |
| ▸ | HAT1 | O14929 | 2/20 | 0.35 |
| ▸ | EP300 | Q09472 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31048600 | 0.88 | KIT (0.39) | KCNH2EP300 | |
| SCHEMBL31048556 | 0.86 | PROKR1 (0.36) | LMNAMAPTPROKR1HSP90AA1HSP90AB1 | |
| SCHEMBL31048666 | 0.85 | PTGES (0.35) | KCNH2 | |
| SCHEMBL31048588 | 0.85 | PDK2 (0.36) | KCNH2PROKR1LRRK2IDO1 | |
| SCHEMBL31048677 | 0.85 | TBK1 (0.35) | KCNH2PROKR1LRRK2 | |
| SCHEMBL31048685 | 0.85 | PDK2 (0.37) | KCNH2PROKR1LRRK2IDO1 | |
| SCHEMBL31048579 | 0.84 | F11 (0.38) | — | |
| SCHEMBL31048568 | 0.84 | S1PR1 (0.39) | KDM4EALDH1A1MAPK1 | |
| SCHEMBL31048716 | 0.83 | GRM4 (0.46) | KCNH2KDM4EALDH1A1MAPTMAPK1 | |
| SCHEMBL31048541 | 0.83 | GSK3B (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4662204-A2 | TELOMERASE INHIBITOR COMPOUNDS | Geron Corporation (US) | 2025-12-17 | — | — | EP | disclosed |
| US-20240343713-A1 | TELOMERASE INHIBITOR COMPOUNDS | BIOPHARMA CREDIT PLC [COLLATERAL AGENT] (GB) | 2024-10-17 | — | — | US | disclosed |
| WO-2024168165-A2 | TELOMERASE INHIBITOR COMPOUNDS | GERON CORPORATION (US) | 2024-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240343713-A1 | TELOMERASE INHIBITOR COMPOUNDS | TERT, POT1, TERF2 | KCNH2 4520/4885KDM4E 509/4885ALDH1A1 606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.